IL132808A - History of carbon-converted erythromycin and azithromycin at position 4 ", their preparation and their pharmaceutical preparations - Google Patents

History of carbon-converted erythromycin and azithromycin at position 4 ", their preparation and their pharmaceutical preparations

Info

Publication number
IL132808A
IL132808A IL13280898A IL13280898A IL132808A IL 132808 A IL132808 A IL 132808A IL 13280898 A IL13280898 A IL 13280898A IL 13280898 A IL13280898 A IL 13280898A IL 132808 A IL132808 A IL 132808A
Authority
IL
Israel
Prior art keywords
compound
formula
membered
optionally substituted
groups
Prior art date
Application number
IL13280898A
Other languages
English (en)
Hebrew (he)
Other versions
IL132808A0 (en
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Priority to IL15733698A priority Critical patent/IL157336A0/xx
Priority to IL15733798A priority patent/IL157337A0/xx
Publication of IL132808A0 publication Critical patent/IL132808A0/xx
Publication of IL132808A publication Critical patent/IL132808A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL13280898A 1997-06-11 1998-05-25 History of carbon-converted erythromycin and azithromycin at position 4 ", their preparation and their pharmaceutical preparations IL132808A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL15733698A IL157336A0 (en) 1997-06-11 1998-05-25 Intermediates in the preparation of c-4"-substituted erythromycin and azithromycin derivatives
IL15733798A IL157337A0 (en) 1997-06-11 1998-05-25 Intermediates in the preparation of c-4"-substituted erythromycin and azithromycin derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4998097P 1997-06-11 1997-06-11
PCT/IB1998/000799 WO1998056801A1 (en) 1997-06-11 1998-05-25 C-4''-substituted macrolide derivatives

Publications (2)

Publication Number Publication Date
IL132808A0 IL132808A0 (en) 2001-03-19
IL132808A true IL132808A (en) 2004-08-31

Family

ID=21962765

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13280898A IL132808A (en) 1997-06-11 1998-05-25 History of carbon-converted erythromycin and azithromycin at position 4 ", their preparation and their pharmaceutical preparations

Country Status (40)

Country Link
EP (1) EP0988309B1 (es)
JP (1) JP3262806B2 (es)
KR (1) KR100369959B1 (es)
CN (1) CN1145636C (es)
AP (1) AP1189A (es)
AR (1) AR013085A1 (es)
AT (1) ATE310742T1 (es)
AU (1) AU745006C (es)
BG (1) BG64357B1 (es)
BR (1) BR9810097A (es)
CA (1) CA2293397C (es)
CO (1) CO4950584A1 (es)
DE (1) DE69832486T2 (es)
DZ (1) DZ2515A1 (es)
EA (1) EA002440B1 (es)
ES (1) ES2251081T3 (es)
GT (1) GT199800075A (es)
HK (1) HK1025974A1 (es)
HN (1) HN1998000074A (es)
HR (1) HRP980315A2 (es)
HU (1) HUP0004076A3 (es)
ID (1) ID24530A (es)
IL (1) IL132808A (es)
IS (1) IS1979B (es)
MA (1) MA24563A1 (es)
MY (1) MY133027A (es)
NO (1) NO315560B1 (es)
NZ (1) NZ500652A (es)
OA (1) OA11226A (es)
PA (1) PA8452001A1 (es)
PE (1) PE79999A1 (es)
PL (1) PL337497A1 (es)
SK (1) SK168299A3 (es)
TN (1) TNSN98084A1 (es)
TW (2) TW200418871A (es)
UA (1) UA70298C2 (es)
UY (1) UY25041A1 (es)
WO (1) WO1998056801A1 (es)
YU (1) YU62999A (es)
ZA (1) ZA985016B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU731842B2 (en) * 1997-09-10 2001-04-05 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
US6339063B1 (en) 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
EP1779853A3 (en) * 1997-09-10 2010-01-27 Merial Ltd. 9a-azalides as veterinary antimicrobial agents
AP9801420A0 (en) * 1998-01-02 1998-12-31 Pfizer Prod Inc Novel macrolides.
US6043227A (en) * 1998-08-19 2000-03-28 Pfizer Inc. C11 carbamates of macrolide antibacterials
EP1437360A3 (en) * 1998-08-19 2005-04-06 Pfizer Products Inc. C11 Carbamates of macrolide antibacterials
US6100240A (en) * 1998-10-09 2000-08-08 Pfizer Inc Macrolide derivatives
SK5812001A3 (en) 1998-11-03 2001-12-03 Pfizer Prod Inc Novel macrolide antibiotics
CA2411293A1 (en) * 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
DE60025370T2 (de) * 1999-08-24 2006-09-21 Abbott Laboratories, Abbott Park 9a-azalide mit antibakterieller wirkung
US6764996B1 (en) 1999-08-24 2004-07-20 Abbott Laboratories 9a-azalides with antibacterial activity
MXPA02007305A (es) * 2000-01-27 2002-11-29 Pfizer Prod Inc Composiciones antiboticas de azalida.
BR0209241A (pt) * 2001-04-27 2004-06-15 Pfizer Prod Inc Processo para preparação de derivados de9-deoxo-9a-aza-9a-homoeritromicina a 4-substituida
JP2003040782A (ja) * 2001-05-31 2003-02-13 Pfizer Prod Inc アザリド抗生物質組成物
CN1665831A (zh) 2002-07-08 2005-09-07 普利瓦研究院有限公司 作为甾类/非甾类抗炎、抗肿瘤和抗病毒活性分子载体的新化合物、组合物
NZ537716A (en) * 2002-07-08 2007-05-31 Glaxosmithkline Zagreb Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
RS20050008A (en) 2002-07-08 2007-06-04 Pliva-Istraživački Institut D.O.O., New compounds,compositions and methods for treatment of inflammatory diseases and conditions
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
US7601695B2 (en) * 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
US7276487B2 (en) 2003-09-23 2007-10-02 Enanta Pharmaceuticals, Inc. 9a, 11-3C-bicyclic 9a-azalide derivatives
EP2716647A3 (en) 2004-02-27 2014-08-20 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
JPWO2009019868A1 (ja) 2007-08-06 2010-10-28 大正製薬株式会社 １０ａ、１２位架橋型１０ａ−アザライド化合物
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US8299035B2 (en) 2008-05-15 2012-10-30 Taisho Pharmaceutucal Co., Ltd. 10a-azalide compound having 4-membered ring structure
DK2358379T3 (en) 2008-10-24 2016-03-07 Cempra Pharmaceuticals Inc BIOFORSVAR USING TRIAZOLHOLDIGE macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2532455T3 (es) * 2010-09-20 2015-03-27 Novartis Tiergesundheit Ag Nuevo procedimiento de preparación de 9-desoxo-9a-aza-9a-homoeritromicina modificada en el C-4'' del anillo de cladinosa por un grupo epóxido
AR085286A1 (es) * 2011-02-21 2013-09-18 Taisho Pharmaceutical Co Ltd Derivado de macrolido sustituido en la posicion c-4
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
JP5857008B2 (ja) * 2012-08-20 2016-02-10 大正製薬株式会社 Ｃ−４”位置換マクロライド誘導体を含有する医薬
CA3130061C (en) * 2013-04-04 2024-05-28 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
CN103965273B (zh) * 2013-08-23 2016-05-25 普莱柯生物工程股份有限公司 一种大环内酯类化合物
CN105669798B (zh) * 2013-08-23 2019-07-26 普莱柯生物工程股份有限公司 一种大环内酯类化合物
AR102810A1 (es) 2014-08-18 2017-03-29 Taisho Pharmaceutical Co Ltd Derivado de macrólido sustituido en la posición c-4
CA2963815A1 (en) 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
CA2980315A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
CN108003207B (zh) 2017-12-19 2019-05-10 海门慧聚药业有限公司 制备泰拉霉素的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150220A (en) * 1977-02-04 1979-04-17 Pfizer Inc. Semi-synthetic 4"-erythromycin A derivatives
SE445223B (sv) * 1977-02-04 1986-06-09 Pfizer Sett att framstella 4"-amino-erytomylin-a-derivat
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
GR80277B (en) * 1983-09-06 1985-01-04 Pfizer Azahomoerythromycin b derivatives and intermediates therefor
US4512982A (en) * 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
CA2064634C (en) * 1991-04-04 1998-08-04 James V. Heck 9-deoxo-8a-aza-8a-homoerythromycin a derivatives modified at the 4"- and8a-positions
US5441939A (en) * 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
US5412982A (en) * 1994-03-10 1995-05-09 Potts; James K. Windsock support

Also Published As

Publication number Publication date
BG103969A (en) 2000-07-31
AP9801254A0 (en) 1998-06-30
TNSN98084A1 (fr) 2005-03-15
PA8452001A1 (es) 2000-05-24
BR9810097A (pt) 2000-08-08
PL337497A1 (en) 2000-08-28
ID24530A (id) 2000-07-20
UY25041A1 (es) 2000-09-29
TWI224106B (en) 2004-11-21
HUP0004076A2 (hu) 2001-04-28
IS5250A (is) 1999-11-16
HUP0004076A3 (en) 2003-05-28
EA199901014A1 (ru) 2000-06-26
IS1979B (is) 2005-01-14
CA2293397C (en) 2004-08-31
HRP980315A2 (en) 1999-04-30
DE69832486T2 (de) 2006-07-27
AU745006B2 (en) 2002-03-07
MA24563A1 (fr) 1998-12-31
ATE310742T1 (de) 2005-12-15
AU745006C (en) 2006-02-23
HN1998000074A (es) 1999-01-08
DZ2515A1 (fr) 2003-02-01
CN1145636C (zh) 2004-04-14
EA002440B1 (ru) 2002-04-25
JP2000514097A (ja) 2000-10-24
HK1025974A1 (en) 2000-12-01
JP3262806B2 (ja) 2002-03-04
ZA985016B (en) 1999-12-10
ES2251081T3 (es) 2006-04-16
DE69832486D1 (de) 2005-12-29
NO996107D0 (no) 1999-12-10
NO996107L (no) 2000-02-10
AU7228198A (en) 1998-12-30
WO1998056801A1 (en) 1998-12-17
MY133027A (en) 2007-10-31
AR013085A1 (es) 2000-12-13
IL132808A0 (en) 2001-03-19
GT199800075A (es) 1999-11-30
TW200418871A (en) 2004-10-01
UA70298A (uk) 2004-10-15
YU62999A (sh) 2002-10-18
CN1259955A (zh) 2000-07-12
SK168299A3 (en) 2000-09-12
UA70298C2 (uk) 2004-10-15
BG64357B1 (bg) 2004-11-30
CA2293397A1 (en) 1998-12-17
EP0988309B1 (en) 2005-11-23
OA11226A (en) 2003-07-16
KR20010013633A (ko) 2001-02-26
NZ500652A (en) 2001-10-26
AP1189A (en) 2003-07-16
KR100369959B1 (ko) 2003-02-12
EP0988309A1 (en) 2000-03-29
CO4950584A1 (es) 2000-09-01
PE79999A1 (es) 1999-08-25
NO315560B1 (no) 2003-09-22

Similar Documents

Publication Publication Date Title
US6420536B1 (en) 4″-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
EP0988309B1 (en) C-4''-substituted macrolide derivatives
US6576749B2 (en) C-4″-substituted macrolide derivatives
EP0984019B1 (en) C11 carbamates of macrolide antibacterials
IL142631A (en) 13-membered azalides, their preparation and pharmaceutical compositions containing them
MXPA99011496A (es) Derivados de macrolidos c-4"sustituidos
CZ438999A3 (cs) C-4"- substituované makrolidové deriváty
MXPA99011495A (es) Derivados de 9-desoxo-9a-homoeritromicina a c-4"sustituidos
EP1437360A2 (en) C11 Carbamates of macrolide antibacterials

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees